Real-world outcomes in patients with moderate-to-severe plaque psoriasis treated with guselkumab for up to 1 year.
Marco GalluzzoMarina TalamontiNicoletta BernardiniAndrea ChiricozziClara De SimoneClaudio BonifatiPierluigi BruniFederico DiotalleviMaria EspositoDario GraceffaKatharina HanselFrancesco LoconsoleGaia MorettaCristina MughedduManuela PapiniAntonio Giovanni RichettaNevena SkrozaLaura AtzoriMaria-Concetta FargnoliSeverino PersechinoAnnamaria OffidaniLuca StingeniKetty PerisConcetta PotenzaLuca BianchiPublished in: Expert opinion on biological therapy (2022)
Guselkumab maintains its efficacy for up to 12 months among responders in a real-world cohort of patients with moderate-severe plaque psoriasis, confirming data from prior real-world studies with smaller cohorts and shorter duration of follow-up.